Image Credit: STAT News
STAT+: Why Stoke Therapeutics’ Dravet syndrome drug is worth watching
Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial for its experimental drug for Dravet syndrome.